Head and Neck TumorsHead and Neck TumorsОпухоли головы и шеи2222-14682411-4634Publishing House ABV Press8710.17650/2222-1468-2012-0-3-63-65ORIGINAL REPORTSОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯGEFITINIB (IRESSA) IN THE TREATMENT OF BRAIN METASTASES FROM NON-SMALL CELL LUNG CARCINOMAГЕФИТИНИБ (ИРЕССА) В ЛЕЧЕНИИ МЕТАСТАЗОВ НЕМЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКОГО В ГОЛОВНОМ МОЗГЕNaskhletashviliD. R.НасхлеташвилиД. Р.
Russian Federation
nas-david@yandex.ruGorbunovaV. A.ГорбуноваВ. А.
Russian Federation
BychkovM. B.БычковМ. Б.
Russian Federation
BekyashevA. Kh.БекяшевА. Х.
Russian Federation
KarakhanV. B.КараханВ. Б.
Russian Federation
AleshinV. A.АлешинВ. А.
Russian Federation
BelovD. M.БеловД. М.
Russian Federation
MoskvinaE. A.МосквинаЕ. А.
Russian Federation
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБНУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, МоскваГБОУ ДПО «Российская медицинская академия последипломного образования» Минздрава России, МоскваN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowОтделение опухолей черепно-челюстно-лицевой области НИИ клинической онкологии ФГБНУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, МоскваN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБНУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва150420122363651804201518042015Copyright ©; 2012, Naskhletashvili D.R., Gorbunova V.A., Bychkov M.B., Bekyashev A.K., Karakhan V.B., Aleshin V.A., Belov D.M., Moskvina E.A.Copyright ©; 2012, Насхлеташвили Д.Р., Горбунова В.А., Бычков М.Б., Бекяшев А.Х., Карахан В.Б., Алешин В.А., Белов Д.М., Москвина Е.А.2012Naskhletashvili D.R., Gorbunova V.A., Bychkov M.B., Bekyashev A.K., Karakhan V.B., Aleshin V.A., Belov D.M., Moskvina E.A.Насхлеташвили Д.Р., Горбунова В.А., Бычков М.Б., Бекяшев А.Х., Карахан В.Б., Алешин В.А., Белов Д.М., Москвина Е.А.https://creativecommons.org/licenses/by/4.0https://ogsh.abvpress.ru/jour/article/view/87

Since 2006, the N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, has been conducting an investigation of the efficiency of targeted therapy with gefitinib in patients with brain metastasis from non-small cell lung carcinoma (NSCLC). The evaluation of treatment efficiency in 9 patients with tumor EGFR mutation in NSCLC revealed that 1 (11.1 %) and 5 (55.6 %) patients achieved complete and partial regression, respectively; disease stabilization was observed in 3 (33.3 %). The median time to progression was 7 months; the patients did not achieve the median survival. The evaluation of treatment efficiency in a group of 6 patients without tumor EGFR mutation or its evidence showed complete and partial tumor regressions; disease stabilization was noted in 3 (50.0 %); disease progression was in 3 (50 %). The median time to progression was 2 months; the median survival was 5 months. Thus, the high efficiency of treatment with the EGFR inhibitor gefitinib in patients with brain metastases from NSCLS was achieved only in a group of patients with found ECFR mutations in exons 18–21 in the tumor. Determination of the status of ECFR in the tumor is the most important prognostic factor when using therapy with the EGFR tyrosine kinase inhibitor gefitinib in patients with brain metastases. The investigation is being continued. 

brainmetastasesgefitinibголовной мозгметастазыгефитиниб1. Cappuzzo F., Calandidi C., Bartolini S. et al. ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases. Br J Cancer 2003;89:246–7.Cappuzzo F., Calandidi C., Bartolini S. et al. ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases. Br J Cancer 2003;89:246–7.2. Gaspar L., Scott C. Rotman L. et al. Recursive partitioning analisys (RPA) of prognostic factors in there Radiation Therapy Oncology Groups (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745–51.Gaspar L., Scott C. Rotman L. et al. Recursive partitioning analisys (RPA) of prognostic factors in there Radiation Therapy Oncology Groups (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745–51.3. Gurpide A., Perez-Gracia J.L., Lopez- Picazo J.M. et al. Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung cancer: two case reports and review of the literature. Clinical Lung Cancer 2005 Sep;7(2):138–40.Gurpide A., Perez-Gracia J.L., Lopez- Picazo J.M. et al. Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung cancer: two case reports and review of the literature. Clinical Lung Cancer 2005 Sep;7(2):138–40.4. Kim K., Lee D.H., Lee J. et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutations. J Clin Oncol 2011;29(suppl; abstr. 7606).Kim K., Lee D.H., Lee J. et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutations. J Clin Oncol 2011;29(suppl; abstr. 7606).5. Li Z., Lu J., Zhao Y. et al. The retrospective analysis of the frequency of EGFR mutations and the efficacy of gefitinib in NSCLC patients with brain metastasis. J Clin Oncol 2011;29(suppl; abstr. e18065).Li Z., Lu J., Zhao Y. et al. The retrospective analysis of the frequency of EGFR mutations and the efficacy of gefitinib in NSCLC patients with brain metastasis. J Clin Oncol 2011;29(suppl; abstr. e18065).6. Maemondo M., Inoue A., Kobayashi K. et al. Gefitinib or chemotherapy for nonsmall- cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380–8.Maemondo M., Inoue A., Kobayashi K. et al. Gefitinib or chemotherapy for nonsmall- cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380–8.7. Mok T.S., Wu Y.L., Thongprasert S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947–57.Mok T.S., Wu Y.L., Thongprasert S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947–57.8. Namba Y., Kijima T., Yokota S. et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer : review of 15 clinical cases. Clinical Lung Cancer 2004;6(2):123–8.Namba Y., Kijima T., Yokota S. et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer : review of 15 clinical cases. Clinical Lung Cancer 2004;6(2):123–8.9. Poon A.N., Ho S.S., Yeo W., Mok T.S. Brain metastasis responding to gefitinib alone. Oncology 2004;67(2):174–8.Poon A.N., Ho S.S., Yeo W., Mok T.S. Brain metastasis responding to gefitinib alone. Oncology 2004;67(2):174–8.10. Yang C.H., Fukuoka M., Mok T.S. et al. Final overall survival results from a phase III randomized, open-label, first-line study of gefitinib vs carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Ann Oncol 2010;21(suppl. 8):viii1.Yang C.H., Fukuoka M., Mok T.S. et al. Final overall survival results from a phase III randomized, open-label, first-line study of gefitinib vs carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Ann Oncol 2010;21(suppl. 8):viii1.